Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
Parkinson’s disease, which is lifelong, progressive, and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the ...
ovarian cancer, malignant ascites, gastric cancer cBR96-doxorubicin immunoconjugate: mab: humanized: Lewis-Y antigen: cancer Cedelizumab [47] mab: humanized: CD4: prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin ...
As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, treatment and risk management that have been made in 2024.
Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors. [14] [11] [7]In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.
Parkinson’s is a degenerative brain disorder that impacts the nervous system and can cause symptoms like tremors, slurred speech and balance and mobility problems.
Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).